Trial Profile
A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary) ; Bortezomib; Carfilzomib; Clarithromycin; Cyclophosphamide; Dexamethasone; Methylprednisolone; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Oncotherapeutics.
- 01 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 01 Oct 2022 Results assessing safety and efficacy of pomalidomide as a replacement for lenalidomide among patients with RRMM, published in the Experimental Hematology
- 12 Aug 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.